Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency

INTRODUCTION: An investigational 10% liquid intravenous immunoglobulin (IVIG) was studied in 63 patients with primary immunodeficiency (PID) at 15 study sites. METHODS: Patients were treated every 3 or 4 weeks with 254–1029 mg/kg/infusion of IVIG. RESULTS: Overall, Biotest-IVIG infusions were well t...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Wasserman, Richard L., Church, Joseph A., Stein, Mark, Moy, James, White, Martha, Strausbaugh, Steven, Schroeder, Harry, Ballow, Mark, Harris, James, Melamed, Isaac, Elkayam, David, Lumry, William, Suez, Daniel, Rehman, Syed M.
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2012
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3389237/
https://ncbi.nlm.nih.gov/pubmed/22392046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-012-9656-5
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki